305 related articles for article (PubMed ID: 34884853)
1. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma.
Ebeling Barbier C; Heindryckx F; Lennernäs H
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884853
[TBL] [Abstract][Full Text] [Related]
2. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.
Nouri YM; Kim JH; Yoon HK; Ko HK; Shin JH; Gwon DI
Korean J Radiol; 2019 Jan; 20(1):34-49. PubMed ID: 30627020
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
Woo HY; Heo J
Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1.
Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G
Expert Opin Drug Deliv; 2013 May; 10(5):679-90. PubMed ID: 23406440
[TBL] [Abstract][Full Text] [Related]
5. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
6. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
[TBL] [Abstract][Full Text] [Related]
7. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review.
Horikawa M; Miyayama S; Irie T; Kaji T; Arai Y
AJR Am J Roentgenol; 2015 Oct; 205(4):764-73. PubMed ID: 26397324
[TBL] [Abstract][Full Text] [Related]
8. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
Idée JM; Guiu B
Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
[TBL] [Abstract][Full Text] [Related]
9. Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.
Matsui O
Clin Drug Investig; 2012 Aug; 32 Suppl 2():3-13. PubMed ID: 22873623
[TBL] [Abstract][Full Text] [Related]
10. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
11. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
12. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques.
Young S; Craig P; Golzarian J
Eur Radiol; 2019 Jun; 29(6):3287-3295. PubMed ID: 30350163
[TBL] [Abstract][Full Text] [Related]
13. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Shin SW
Korean J Radiol; 2009; 10(5):425-34. PubMed ID: 19721826
[TBL] [Abstract][Full Text] [Related]
14. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
15. Cirrhotic hepatocellular carcinoma-based decellularized liver cancer model for local chemoembolization evaluation.
Wang M; Gao Y; Liu X; Li Z; Xiao J; Gao X; Gibson MI; Guo Q
Acta Biomater; 2024 Mar; 176():144-155. PubMed ID: 38244660
[TBL] [Abstract][Full Text] [Related]
16. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
[TBL] [Abstract][Full Text] [Related]
17. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller.
Kim JW; Kim JH; Sung KB; Ko HK; Shin JH; Kim PN; Choi HK; Ko GY; Yoon HK; Chun SY; Gwon DI
Am J Gastroenterol; 2014 Aug; 109(8):1234-40. PubMed ID: 24935276
[TBL] [Abstract][Full Text] [Related]
20. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
